

Appl. No. : 09/486,167
Filed : August 15, 2000

AMENDMENTS TO THE CLAIMS

Please cancel claims 28-32. Please amend claims 5 and 14 as shown.

Claims 1-4. (Cancelled)

Claim 5. (Currently amended) An isolated or purified polynucleotide consisting-essentially of SEQ ID NO: 1 or its complementary strand.

Claims 6-8. (Cancelled)

Claim 9. (Previously presented) A vector comprising the polynucleotide of claim 5.

Claims 10-11. (Cancelled)

Claim 12. (Previously presented) A diagnostic device comprising the nucleotide of claim 5.

Claim 13. (Withdrawn) A method for the in vitro detection of lung injuries and diseases or oxidative stress-related diseases and disorders, comprising the steps of:

- isolating a sample from a body fluid of a patient,
- contacting said sample with the nucleotide sequence of claim 5 or a portion thereof, and
- detecting a reaction of a molecule present in said sample with said element.

Claim 14. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the nucleotide sequence of claim 5 ~~or a peptide encoded by said nucleotide sequence.~~

Claim 15. (Withdrawn) The method of claim 13 wherein said oxidative stress-related diseases or disorders are selected from the group consisting of: specific cardio-vascular diseases neurodegenerative disorders apoptosis and inflammatory reactions, allergic reactions high bone mass syndrome, osteopetrosis, osteoporosis-pseudoglioma syndrome, and Bardet-Biedl syndrome 1.

Claim 16. (Previously presented) A cell transformed by the vector according to claim 9.

Appl. No. : 09/486,167
Filed : August 15, 2000

Claim 17. (Withdrawn) A non-human transgenic animal, transformed by the vector according to claim 9 or comprising a partial or total genomic deletion of SEQ ID NO:1, or a homologue thereof.

Claim 18. (Withdrawn) The method of claim 13, wherein said oxidative stress-related diseases and disorders are inflammatory diseases.

Claim 19. (Withdrawn) The method of claim 13, further comprising the step of inhibiting the contaminants present in said sample.

Claim 20. (Withdrawn) The method of claim 13, wherein said patient is a human patient.

Claim 21. (Withdrawn) The method of claim 15 wherein said specific cardio-vascular diseases is arteriosclerosis.

Claim 22. (Withdrawn) The method of claim 15 wherein said neurodegenerative disorders are selected from the group consisting of: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Claim 23. (Withdrawn) The method of claim 15 wherein said allergic reactions are selected from the group consisting of: asthma, hay fever and eczema.

Claim 24. (Withdrawn) The transgenic animal of claim 16, wherein said animal is a mammal.

Claim 25. (Withdrawn) The diagnostic device of Claim 12 further comprising the amino acid sequence encoded by the nucleotide sequence of Claim 5 and/or an antibody which recognizes the amino acid sequence encoded by the nucleotide sequence of Claim 5.

Claim 26. (Withdrawn) The method of Claim 13, further comprising, contacting said sample with the amino acid sequence encoded by the nucleotide sequence of Claim 5 and/or an antibody which recognizes the amino acid sequence encoded by the nucleotide sequence of Claim 5.

Claim 27. (Withdrawn) The pharmaceutical composition of Claim 14, further comprising, the amino acid sequence encoded by the nucleotide sequence of Claim 5 and/or an antibody which recognizes the amino acid sequence encoded by the nucleotide sequence of Claim 5.

Claims 28-32. (Cancelled)